Search Our Site

News filed in:

"medical"

Cellectis publishes description of new ‘all-in-one’ CAR-T architecture

One of the companies developing CAR-T therapies that don’t require patients to have their own T cells harvested has developed an architecture that it said could streamline manufacturing and improve safety. French biotech firm Cellectis said Tuesday that it had published a study describing the development of CubiCAR, an “all-in-one” architecture that embeds a multi-function... Read More »

Read More →

One of the companies developing CAR-T therapies that don’t require patients to have their own T cells harvested has developed an architecture that it said could streamline manufacturing and improve safety. French biotech firm Cellectis said Tuesday that it had published a study describing the development of CubiCAR, an “all-in-one” architecture that embeds a multi-function… Read More »

[...]

Read More

Nearly Half of Patients in Trial Respond to Checkpoint Inhibitor Treatment for Common Skin Cancer

Cutaneous squamous cell carcinoma is the second most common skin cancer, with an estimated 1 million new cases diagnosed annually. However, there are currently no systemic therapies approved for the treatment of advanced cutaneous squamous-cell carcinoma in patients who show no progress with surgery or radiation. According to recent clinical trials, an immune checkpoint inhibitor... Read More »

Read More →

Cutaneous squamous cell carcinoma is the second most common skin cancer, with an estimated 1 million new cases diagnosed annually. However, there are currently no systemic therapies approved for the treatment of advanced cutaneous squamous-cell carcinoma in patients who show no progress with surgery or radiation. According to recent clinical trials, an immune checkpoint inhibitor… Read More »

[...]

Read More

Sunitinib (Sutent) May Spare Some Kidney Cancer Patients From Organ Removal

Many people with advanced kidney cancer might not need to have their kidneys removed during treatment, something that until now has been standard practice. Patients who only received a targeted drug for their kidney cancer survived just as well as those who had their cancerous organ removed before drug therapy, according to a new clinical... Read More »

Read More →

Many people with advanced kidney cancer might not need to have their kidneys removed during treatment, something that until now has been standard practice. Patients who only received a targeted drug for their kidney cancer survived just as well as those who had their cancerous organ removed before drug therapy, according to a new clinical… Read More »

[...]

Read More

First 3D-printed human corneas

The first human corneas have been 3D printed by scientists at Newcastle University, UK. It means the technique could be used in the future to ensure an unlimited supply of corneas. As the outermost layer of the human eye, the cornea has an important role in focusing vision. Yet there is a significant shortage of... Read More »

Read More →

The first human corneas have been 3D printed by scientists at Newcastle University, UK. It means the technique could be used in the future to ensure an unlimited supply of corneas. As the outermost layer of the human eye, the cornea has an important role in focusing vision. Yet there is a significant shortage of… Read More »

[...]

Read More

Penn Docs Have Performed the World’s First Robot-Assisted Spinal Surgery

Surgeons at Penn have officially made history after successfully completing the world’s first robotically assisted spinal surgery, the institution has announced. Doctors completed the procedure last August over two days and more than 20 hours. Now nine months later, the patient is back to his normal life. Noah Pernikoff, a 27-year-old commercial contractor living in... Read More »

Read More →

Surgeons at Penn have officially made history after successfully completing the world’s first robotically assisted spinal surgery, the institution has announced. Doctors completed the procedure last August over two days and more than 20 hours. Now nine months later, the patient is back to his normal life. Noah Pernikoff, a 27-year-old commercial contractor living in… Read More »

[...]

Read More

‘There’s other s— in the vial’: Bombshel lawsuit claims no one knows exactly what’s in a drug that costs the government over $1 billion

Mallinckrodt Pharmaceuticals’ blockbuster drug Acthar has been one of the biggest drug-related expenses for the government’s Medicare program. In 2015 alone Medicare spent $500 million on it. The drug is primarily indicated to treat infantile spasms. Medicare is a program for the elderly. One whistleblower claims that Mallinckrodt has engaged in an elaborate scheme to... Read More »

Read More →

Mallinckrodt Pharmaceuticals’ blockbuster drug Acthar has been one of the biggest drug-related expenses for the government’s Medicare program. In 2015 alone Medicare spent $500 million on it. The drug is primarily indicated to treat infantile spasms. Medicare is a program for the elderly. One whistleblower claims that Mallinckrodt has engaged in an elaborate scheme to… Read More »

[...]

Read More

Treatment combo nearly doubles survival time in lung cancer patients, study finds

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. The study results apply only to patients whose lung cancer does not begin in the squamous cells (or surface lung... Read More »

Read More →

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed. The study results apply only to patients whose lung cancer does not begin in the squamous cells (or surface lung… Read More »

[...]

Read More

Hundreds of deaths possibly linked to Parkinson’s disease drug made by San Diego’s Acadia

Hundreds of patients have died while taking a Parkinson’s disease drug from San Diego’s Acadia Pharmaceuticals, according to a story by CNN. In addition, the story said many other patients weren’t benefiting from the drug, meant to control Parkinson’s disease psychosis. A total of more than 700 patients taking the drug, Nuplazid, have died in... Read More »

Read More →

Hundreds of patients have died while taking a Parkinson’s disease drug from San Diego’s Acadia Pharmaceuticals, according to a story by CNN. In addition, the story said many other patients weren’t benefiting from the drug, meant to control Parkinson’s disease psychosis. A total of more than 700 patients taking the drug, Nuplazid, have died in… Read More »

[...]

Read More

Machines see the future for patients diagnosed with brain tumors

For patients diagnosed with glioma, a deadly form of brain tumor, the future can be very uncertain. While gliomas are often fatal within two years of diagnosis, some patients can survive for 10 years or more. Predicting the course of a patient’s disease at diagnosis is critical in selecting the right therapy and in helping... Read More »

Read More →

For patients diagnosed with glioma, a deadly form of brain tumor, the future can be very uncertain. While gliomas are often fatal within two years of diagnosis, some patients can survive for 10 years or more. Predicting the course of a patient’s disease at diagnosis is critical in selecting the right therapy and in helping… Read More »

[...]

Read More

Magnetic Heart Pump Cuts Risk of Blood Clots, Stroke in Study

A new heart pump cuts the risk of blood clots and stroke in patients with heart failure, research funded by the device maker shows. The study included 366 patients who received either Abbott Inc.’s HeartMate 3 left ventricular assist device or the HeartMate II. Two years after getting the devices, 151 of the 190 patients... Read More »

Read More →

A new heart pump cuts the risk of blood clots and stroke in patients with heart failure, research funded by the device maker shows. The study included 366 patients who received either Abbott Inc.’s HeartMate 3 left ventricular assist device or the HeartMate II. Two years after getting the devices, 151 of the 190 patients… Read More »

[...]

Read More

Page 1 of 13

Categories
Archives